ReviewJournal of physiology and biochemistry2026
The endocannabinoidome-microbiota axis in obesity: a potential link to colorectal cancer development.
Review in Journal of physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a multifactorial disease strongly influenced by genetic and environmental factors, as well as by immune and metabolic disorders such as obesity and gut dysbiosis. Recent evidence highlights the interplay between the endocannabinoidome (eCBome) and the gut microbiota as a central regulatory axis of intestinal homeostasis, metabolism, and immune responses. Although no studies have directly investigated this functional interaction in the CRC context, recent evidence suggests that dysfunction of the eCBome-microbiota axis, commonly observed in obesity, may influence colorectal tumorigenesis by impairing intestinal barrier integrity, increasing endotoxemia and immune dysregulation, altering microbial metabolite production, and activating NF-κB-mediated pro-tumorigenic signaling pathway. This is the first review to comprehensively integrate current evidence linking obesity-associated eCBome-microbiota dysfunction with CRC-related mechanisms and to propose potential pathways through which this interaction may influence CRC pathogenesis, providing a framework to guide future studies and support the development of novel preventive and therapeutic strategies for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.